Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein

A rabies virus, glycoprotein technology, applied in the direction of antiviral immunoglobulin, antiviral agent, antibody, etc., can solve the problems of infection, limited application, and limitation of mass production

Active Publication Date: 2010-08-25
NCPC NEW DRUG RES & DEV
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most McAbs are of mouse origin, and the heterogeneous reaction of mouse McAbs greatly limits the application of McAbs as therapeutic agents in humans.
As an antibody component, immunoglobulin (Vaccinia immune globulin, VIG) mainly comes from the immune serum of donors (convalescent patients), and it takes a lot of manpower and financial resources to obtain positive serum and pass the safety test, which makes its mass production difficult. Restricted, and because it comes from serum, it is prone to infection of blood-borne diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein
  • Humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein
  • Humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] The specific implementation manners of the present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention.

[0027] Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art.

[0028]Materials and methods

[0029] 1. Viruses, cells, and vectors: rabies virus aG strain, CTN strain, CVS strain and ERA strain were provided by the Institute of Viral Disease Prevention and Control, Chinese Center for Disease Control and Prevention. The PM strain used for human immunization is an imported human vaccine strain, and the cells used for the neutralization experiment of rabies virus in vitro are BHK-21 (ATCC). The strain is XLI-Blue (Stratagene, USA), and the vector is pComb3 (40kb), provided by Scripps Research I...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein, which is obtained through screening by utilizing phage display technology. The antibody specifically identifies the granule antigen of the rabies virus, is against the rabies virus glycoprotein G, has obvious immunofluorescence reaction and enzyme linked immunosorbent assay with the rabies virus and has the neutralizing activity function against rabies virus infection. The antibody can be prepared into the specific antibody drugs for preventing and treating rabies, thereby being clinically used for preventing and treating rabies caused by the rabies virus.

Description

technical field [0001] The invention relates to genetic engineering antibody technology, in particular to a human-source neutralizing antibody against rabies virus glycoprotein; the invention also relates to the application of the antibody in the preparation of medicaments for preventing or treating rabies. Background technique [0002] Rabies is a worldwide zoonotic disease caused by rabies virus, once the onset of 100% death. Rabies has been reported in 87 countries in the world, and more than 50,000 people die from rabies every year (Knobel DL, et al.2005). Rabies post-exposure prophylaxis is the main measure to prevent and control rabies. For severely exposed people, the World Health Organization (WHO) recommends the use of rabies vaccine injection combined with anti-rabies immune globulin (rabies immune globulin, RIG). The two types of RIG currently in use are human rabies immune globulin (HRIG) and equine rabies immune globulin (ERIG). ERIG has severe side effects a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13C12N15/63C12N1/15C12N1/19C12N1/21C12N5/10G01N33/569A61K39/42A61P31/14
CPCC07K2317/21C07K16/10A61P31/14
Inventor 梁米芳孙丽娜陈哲李川李德新
Owner NCPC NEW DRUG RES & DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com